High efficacy of Rituximab in indolent HCV-related lymphoproliferative disorders asociated with systemic autoimmune diseases

Clinical and Experimental Rheumatology

Volumn 23, Issue 6, 2005, Pages 877-880

  Cervetti, Guilia ^a   Mechelli, Sandra ^a   Riccioni, Rossella ^a   Galimberti, Sara ^a   Caracciolo, Francesco ^a   Petrini, Mario ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Autoimmune diseases; HCV; Rituximab

Indexed keywords

RITUXIMAB; VIRUS RNA;

ADULT; AGED; ALLERGIC RHINITIS; ARTICLE; AUTOIMMUNE DISEASE; CHILL; CLINICAL ARTICLE; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HEPATITIS C VIRUS; HUMAN; LIVER TOXICITY; MALE; MONOTHERAPY; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; AUTOIMMUNE DISEASES; FEMALE; HEPATITIS C, CHRONIC; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 29944439246     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. MORTON LM, ENGELS EA, THEODORE RT et al.: Hepatitis C virus and risk of non-Hodgkin's lymphoma: A population-based case-control study among Connecticut women. Cancer Epidemiol Biomarkers Prev 2004; 13; 425-30.
2. FERRI C, LA CIVITA L, CARACCIOLO F, BELLESI G, ZIGNEGO AL: Hepatitis C virus and lymphoproliferative disorders. Blood 1996 15; 88: 4730-31.
3. MISIANI R, BELLAVITA P, FELINI D et al.: Hepatitis C virus infection in patients with essential mixed cryoglobulinemia. Ann Intern Med 1992; 117: 573-7.
4. DAMMACCO F, SANSONNO D, PICCOLI C et al.: The cryoglobulins: an overview. Eur J Clin Invest 2000; 31: 628-38.
5. WEN-KAI W, LEVY S: Hepatitis C virus (HCV) and lymphomagenesis. Leukemia & lymphoma 2003; 44: 1113-20.
6. HERMINE O, LEFRERE F, BRONOWICKI JP et al.: Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med 2002; 347: 89-94.
7. ZUCKERMAN E, ZUKERMAN T, SAHAR D et al.: The effect of antiviral therapy on t(14;18) translocation and immunoglobulin gene rearragement in patients with chronic hepatitis C virus infection. Blood 2001; 97: 1555-9.
8. TREON SP, ANDERSON KC: The use of rituximab in the treatment of malignant and non malignant plasma cell disorders. Semin Oncol 2000; 27: 79-85.
9. ARMSTRONG DJ, WRIGHT SA, FINCH MB et al.: Active systemic lupus erythematosus successfully treated with Rituximab and oral steroids. Clin Exp Rheumatol 2004; 22: 787-88.
10. KEYSTONE EC: Safety issues to emerging therapies for rheumatoid arthritis. Clin Exp Rheumatol 2004; 22 (Suppl. 35): S148-50.
11. ARNETT FC, EDWORTHY SM, BLOCH DA et al.: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
12. GOREVIC PD, KASSAB HJ, LEVO Y et al.: Mixed cryoglobulinemia: clinical aspects and long-term follow-up of 40 patients. Am J Med 1980; 60: 287-308.
13. GALIMBERTI S, MORABITO F, GUERRINI F et al.: Peripheral blood stem cell contamination evaluated by a highly sensitive molecular method fails to predict outcome of autotransplanted multiple myeloma patients. Br J Haematol 2003;120:405-12.
14. GISBERT JP, GARCIA-BUEY L, PAJERES JM et al.: Prevalence of hepatitis C virus infection in B-cell non-Hodgkin's lymphoma: systematic review and meta-analysis. Gastroenterology 2003; 125: 1723-32.
15. CACOUB P, POYNARD T, GHILLANI P et al.: Extrahepatic manifestations of chronic hepatitis C. Arthitis Rheum 199; 42: 2204-12.
16. PILERI P, UEMATSU Y, CAMPAGNOLI S et al.: Binding of hepatitis C virus to CD81. Science 1998; 282: 938-41.
17. MATSUO K, KUSANO A, SUGUMAR A et al.: Effect of hepatitis C virus infection on the risk of non-Hodgkin's lymphoma: a meta-analysis of epidemiological studies. Cancer Sci 2004; 95: 745-52.
18. RAMOS-CASALS M, TREJO O, GARCIA-CARRASCO M et al.: Triple association between hepatitis C virus infection, systemic autoimmune diseases, and B cell lymphoma. The J Rheumatol 2004; 31: 495-4.
19. LAMBRECT P, LERIN-LOZANO C, MERZ H et al.: Rituximab induces remission in refractory HCV associated cryoglobulinaemic vasculitis. Ann Rheum Dis 2003; 62: 1230-3.
20. WYLAM MR, ANDERSON PM, KUNTZ NL et al.: Successful treatment of refractory myasthenia gravis using Rituximab: a pediatric case report. J Pediatr 2003; 143: 674-7.
21. COOPER HL, HEALY E, THEAKER JM et al.: Treatment of resistant pemphigus vulgaris with an anti-CD20 monoclonal antibody (Rituximab). Clin Exp Dermatol 2003; 28: 366-8.
22. VIRGOLINI L, MARZOCCHI V: Anti-CD20 monoclonal antibody (Rituximab) in the treatment of autoimmune diseases. Successful results in refractory pemphigus vulgaris: report of a case. Haematologica 2003; 88: (07) ELT24.
23. REMUZZI G, CHIURCHIU C, ABBATE M et al.: Rituximab for idiopatic membranous nephropathy. Lancet 2002; 360: 923-24.
24. SASONNO D, DE RE V, LAULETTA G, TUCCI FA et al.: Monoclonal antibody-treatment of mixed cryoglobulinemia resistant to interferon α with an anti-CD20. Blood 2003; 101: 3818-26.
25. RAMBALDI A, LAZZARI M, MANZONI C et al.: Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicolar lymphoma. Blood 2002; 99: 856-62.
26. SACCHI S, FEDERICO M, VITOLO U et al.: Clinical activity and safety of combination immunotherapy with IFN-alpha 2a and Rituximab in patients with relapsed low grade non Hodgkin's lymphoma. Haematologica 2001; 86: 951-8.